CY1121352T1 - Καινοφανες παραγωγο οξιμης χρωμονης και η χρηση του ως αλλοστερικου ρυθμιστη των μεταβοτροπικων υποδοχεων γλουταμικου - Google Patents
Καινοφανες παραγωγο οξιμης χρωμονης και η χρηση του ως αλλοστερικου ρυθμιστη των μεταβοτροπικων υποδοχεων γλουταμικουInfo
- Publication number
- CY1121352T1 CY1121352T1 CY20191100277T CY191100277T CY1121352T1 CY 1121352 T1 CY1121352 T1 CY 1121352T1 CY 20191100277 T CY20191100277 T CY 20191100277T CY 191100277 T CY191100277 T CY 191100277T CY 1121352 T1 CY1121352 T1 CY 1121352T1
- Authority
- CY
- Cyprus
- Prior art keywords
- oximum
- glutamic
- new
- glutamate
- metabotropic receptors
- Prior art date
Links
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 title 1
- 102000006239 metabotropic receptors Human genes 0.000 title 1
- 108020004083 metabotropic receptors Proteins 0.000 title 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 229930195712 glutamate Natural products 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 150000002923 oximes Chemical class 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182468 | 2014-08-27 | ||
| PCT/EP2015/069601 WO2016030444A1 (en) | 2014-08-27 | 2015-08-27 | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121352T1 true CY1121352T1 (el) | 2020-05-29 |
Family
ID=51421865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100277T CY1121352T1 (el) | 2014-08-27 | 2019-03-08 | Καινοφανες παραγωγο οξιμης χρωμονης και η χρηση του ως αλλοστερικου ρυθμιστη των μεταβοτροπικων υποδοχεων γλουταμικου |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10017521B2 (enExample) |
| EP (3) | EP3502115A1 (enExample) |
| JP (1) | JP6430015B2 (enExample) |
| KR (1) | KR101870589B1 (enExample) |
| CN (2) | CN106715444B (enExample) |
| AU (1) | AU2015308438B2 (enExample) |
| CA (1) | CA2956191C (enExample) |
| CY (1) | CY1121352T1 (enExample) |
| DK (1) | DK3186257T3 (enExample) |
| ES (1) | ES2714073T3 (enExample) |
| HR (1) | HRP20190343T1 (enExample) |
| HU (1) | HUE041941T2 (enExample) |
| IL (1) | IL250287B (enExample) |
| LT (1) | LT3186257T (enExample) |
| MA (3) | MA40530A (enExample) |
| ME (1) | ME03339B (enExample) |
| MX (1) | MX369643B (enExample) |
| NZ (1) | NZ728853A (enExample) |
| PL (1) | PL3186257T3 (enExample) |
| PT (1) | PT3186257T (enExample) |
| RS (1) | RS58592B1 (enExample) |
| RU (1) | RU2672569C2 (enExample) |
| SI (1) | SI3186257T1 (enExample) |
| SM (1) | SMT201900152T1 (enExample) |
| TR (1) | TR201903332T4 (enExample) |
| WO (1) | WO2016030444A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3186257T1 (sl) * | 2014-08-27 | 2019-07-31 | Prexton Therapeutics Sa | Novi derivat kromon oksima in njegova uporaba kot alosterični modulator metabotropnih glutamatnih receptorjev |
| US10532057B2 (en) * | 2015-08-27 | 2020-01-14 | Prexton Therapeutics Sa | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
| JP7633676B2 (ja) | 2018-07-26 | 2025-02-20 | ドメイン・セラピューティクス | 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065467A (en) | 1973-12-27 | 1977-12-27 | Carlo Erba, S. P. A. | 5:6-Benzo δ-pyrone derivatives and process for their preparation |
| US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
| JP3993651B2 (ja) * | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| EP1298129A3 (en) | 2001-09-28 | 2003-06-04 | Central Glass Company, Limited | Process for producing 4-sustituted benzopyran derivatives |
| US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
| US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20070027216A1 (en) | 2005-07-15 | 2007-02-01 | Bridget Larson | Novel hydrochloride salts of levodopa |
| WO2009010455A2 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as modulators of metabotropic glutamate receptors |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| JP5806672B2 (ja) * | 2009-10-30 | 2015-11-10 | ドメイン・セラピューティクス | 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用 |
| CN104193761B (zh) * | 2009-12-04 | 2017-10-17 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| WO2013107862A1 (en) * | 2012-01-18 | 2013-07-25 | Addex Pharma S.A. | NOVEL 2-AMINO-4,5,6,8-TETRAHYDROPYRAZOLO[3,4-b]THIAZOLO [4,5-d]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| SI3186257T1 (sl) * | 2014-08-27 | 2019-07-31 | Prexton Therapeutics Sa | Novi derivat kromon oksima in njegova uporaba kot alosterični modulator metabotropnih glutamatnih receptorjev |
| US10532057B2 (en) | 2015-08-27 | 2020-01-14 | Prexton Therapeutics Sa | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
-
2015
- 2015-08-27 SI SI201530640T patent/SI3186257T1/sl unknown
- 2015-08-27 MX MX2017002429A patent/MX369643B/es active IP Right Grant
- 2015-08-27 AU AU2015308438A patent/AU2015308438B2/en not_active Ceased
- 2015-08-27 KR KR1020177005768A patent/KR101870589B1/ko not_active Expired - Fee Related
- 2015-08-27 PT PT15770814T patent/PT3186257T/pt unknown
- 2015-08-27 MA MA040530A patent/MA40530A/fr unknown
- 2015-08-27 WO PCT/EP2015/069601 patent/WO2016030444A1/en not_active Ceased
- 2015-08-27 CN CN201580045432.7A patent/CN106715444B/zh not_active Expired - Fee Related
- 2015-08-27 LT LTEP15770814.0T patent/LT3186257T/lt unknown
- 2015-08-27 EP EP19151429.8A patent/EP3502115A1/en not_active Withdrawn
- 2015-08-27 HU HUE15770814A patent/HUE041941T2/hu unknown
- 2015-08-27 MA MA048048A patent/MA48048A/fr unknown
- 2015-08-27 HR HRP20190343TT patent/HRP20190343T1/hr unknown
- 2015-08-27 CA CA2956191A patent/CA2956191C/en not_active Expired - Fee Related
- 2015-08-27 SM SM20190152T patent/SMT201900152T1/it unknown
- 2015-08-27 ME MEP-2019-59A patent/ME03339B/me unknown
- 2015-08-27 NZ NZ728853A patent/NZ728853A/en not_active IP Right Cessation
- 2015-08-27 ES ES15770814T patent/ES2714073T3/es active Active
- 2015-08-27 TR TR2019/03332T patent/TR201903332T4/tr unknown
- 2015-08-27 US US15/506,941 patent/US10017521B2/en not_active Expired - Fee Related
- 2015-08-27 EP EP15770814.0A patent/EP3186257B1/en active Active
- 2015-08-27 EP EP19217991.9A patent/EP3696183A1/en not_active Withdrawn
- 2015-08-27 DK DK15770814.0T patent/DK3186257T3/en active
- 2015-08-27 PL PL15770814T patent/PL3186257T3/pl unknown
- 2015-08-27 RU RU2017109818A patent/RU2672569C2/ru active
- 2015-08-27 CN CN201910567865.9A patent/CN110343118A/zh active Pending
- 2015-08-27 RS RS20190289A patent/RS58592B1/sr unknown
- 2015-08-27 MA MA052702A patent/MA52702A/fr unknown
- 2015-08-27 JP JP2017530425A patent/JP6430015B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-25 IL IL250287A patent/IL250287B/en active IP Right Grant
-
2018
- 2018-06-05 US US16/000,338 patent/US10442818B2/en active Active
-
2019
- 2019-03-08 CY CY20191100277T patent/CY1121352T1/el unknown
- 2019-09-30 US US16/587,670 patent/US20200024285A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124828T1 (el) | Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης | |
| CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
| BR112018003264A2 (pt) | conjugados de aldeído e usos dos mesmos | |
| MX391221B (es) | Compuestos y composiciones y usos de los mismos. | |
| EA201790806A1 (ru) | Иммунорегулирующие средства | |
| CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| MX382313B (es) | Derivados del sobetiroma. | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| CY1122401T1 (el) | Παραγωγο οξιμης της χρωμονης με ικανοτητα διεισδυσης στον εγκεφαλο για τη θεραπεια της δυσκινησιας που προκαλειται απο λεβοντοπα | |
| MX2020003862A (es) | Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| MX374426B (es) | Sintesis de compuestos de triacetonadiamina mediante procedimiento de aminacion reductora de triacetonadiamina y derivados de los mismos. | |
| MX394123B (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos | |
| CY1121352T1 (el) | Καινοφανες παραγωγο οξιμης χρωμονης και η χρηση του ως αλλοστερικου ρυθμιστη των μεταβοτροπικων υποδοχεων γλουταμικου | |
| BR112016017886A8 (pt) | grelina ou variantes ou derivados da mesma, e, usos da grelina | |
| CY1121650T1 (el) | Αναστολεις συνθασης αλδοστερονης | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| CU24647B1 (es) | Moduladores del receptor nmda heteroaromático | |
| NI201600091A (es) | UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS | |
| MX2019000982A (es) | Compuestos y composiciones y usos de los mismos. | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| CL2019000027A1 (es) | Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes. |